Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The graft-versus-lymphoma effect: clinical review and future opportunities

Bone Marrow Transplantation volume 36, pages 1–17 (2005)Cite this article

Summary:

Numerous lines of preclinical and clinical evidence support the existence of a graft-versus-leukemia effect, but less evidence supporting a comparable graft-versus-lymphoma effect exists. We review here current clinical data addressing the graft-versus-lymphoma effect, including comparisons of autologous, syngeneic, and allogeneic transplantation; responses to immunomodulation; and responses to nonmyeloablative stem cell transplantation. Despite several limitations of the data, we believe that there is sufficient evidence suggesting a significant graft-versus-lymphoma effect. In addition, we discuss approaches for clinical management of lymphoma patients, opportunities for mechanistic studies afforded by donor leukocyte infusions and nonmyeloablative transplantation, and suggestions for clinical studies to further define the magnitude and applicability of the graft-versus-lymphoma effect.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Barnes D, Loutit J, Neal F . Treatment of murine leukemia with X-rays and homologous bone marrow. BMJ 1956; 2: 626–630.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Bortin MM, Rimm AA, Saltzsein EC . Graft-versus-leukaemia: quantification of adoptive immunotherapy in murine leukemia. Science 1973; 79: 811–813.

    Google Scholar 

  3. Bortin MM, Truitt RL, Rimm AA et al. Graft-versus-leukemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature 1979; 281: 490–491.

    CAS  PubMed  Google Scholar 

  4. Weiden PL, Storb R, Tsoi MS et al. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. J Immunol 1976; 1226: 1212–1219.

    Google Scholar 

  5. Luznik L, Fuchs EJ . Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002; 9: 123–137.

    PubMed  Google Scholar 

  6. Gale RP, Champlin RE . How does bone-marrow transplantation cure leukaemia? Lancet 1984; 2: 28–30.

    CAS  PubMed  Google Scholar 

  7. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.

    CAS  PubMed  Google Scholar 

  8. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  CAS  PubMed  Google Scholar 

  9. Mitsuyasu RT, Champlin RE, Gale RP et al. Treatment of donor bone marrow with monoclonal anti T-cell antibody and complement for the prevention of graft-versus-host disease: a prospective, randomized, double-blind trial. Ann Intern Med 1986; 105: 20–26.

    CAS  PubMed  Google Scholar 

  10. Horowitz MM, Gale RP, Sonderl PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  11. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte infusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  12. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204.

    CAS  PubMed  Google Scholar 

  13. Bar BM, Schattenburg A, Mensink EJ et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic born marrow transplantation. J Clin Oncol 1993; 11: 513–519.

    Article  CAS  PubMed  Google Scholar 

  14. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T cell dose. Blood 1993; 82: 2310–2318.

    CAS  PubMed  Google Scholar 

  15. Collins Jr RH, Piniero LA, Nemunaitis JJ et al. Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion 1995; 35: 891–898.

    PubMed  Google Scholar 

  16. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  17. Hertenstein B, Wiesneth M, Novotny J et al. Interferon-alpha and donor buffy coat transfusions for the treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993; 56: 1114–1118.

    CAS  PubMed  Google Scholar 

  18. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100–106.

    CAS  PubMed  Google Scholar 

  19. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377–3383.

    CAS  PubMed  Google Scholar 

  20. Collins Jr RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    PubMed  Google Scholar 

  21. Porter DL, Collins Jr RH, Shpilberg O et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999; 5: 253–261.

    CAS  PubMed  Google Scholar 

  22. Dazzi F, Szydlo RM, Cross NC et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712–2716.

    CAS  PubMed  Google Scholar 

  23. Atra A, Millar B, Shepherd V et al. Donor lymphocyte infusion for childhood acute lymphoblastic leukemia. Bone Marrow Transplant 2002; 29: 63–66.

    Google Scholar 

  24. Porter DL, Roth MS, Lee SJ et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 975–980.

    CAS  PubMed  Google Scholar 

  25. Cervantes F, Rovira M, Urbano-Ispizua A et al. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000; 26: 697–699.

    CAS  PubMed  Google Scholar 

  26. Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.

    CAS  PubMed  Google Scholar 

  27. Verdonck G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.

    Google Scholar 

  28. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myelomas after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211.

    CAS  PubMed  Google Scholar 

  29. Mehta J, Singhal S . Graft-versus-myeloma. Bone Marrow Transplant 1998; 22: 835–843.

    CAS  PubMed  Google Scholar 

  30. Little MT, Storb R . The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain. J Clin Invest 2000; 105: 1679–1681.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000; 25: 345–350.

    CAS  PubMed  Google Scholar 

  32. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  33. Slavin S, Morecki S, Weiss L et al. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy – from bench to patient bedside. Semin Oncol 2004; 31: 4–21.

    PubMed  Google Scholar 

  34. Mielcarek M, Storb R . Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies. Cancer Treat Rev 2003; 29: 283–290.

    CAS  PubMed  Google Scholar 

  35. Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remission in patients with hematological disease. Blood 2003; 101: 1620–1629.

    CAS  PubMed  Google Scholar 

  36. Slavin S, Nagler A, Shapira MY . Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J Clin Immunol 2002; 22: 64–69.

    PubMed  Google Scholar 

  37. Jones RJ, Ambinder RF, Piantadosi S, Santos G . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

    CAS  PubMed  Google Scholar 

  38. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous vs allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050–1055.

    CAS  PubMed  Google Scholar 

  39. Schimmer AD, Jamal S, Messner H, Keating A . Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Bone Marrow Transplant 2000; 26: 859–864.

    CAS  PubMed  Google Scholar 

  40. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic vs autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–4205.

    CAS  PubMed  Google Scholar 

  41. Chopra R, Goldstone AH, Pearce R et al. Autologous vs allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 1992; 10: 1690–1695.

    CAS  PubMed  Google Scholar 

  42. Levine JE, Harris RE, Loberiza Jr FR et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003; 101: 2476–2482.

    CAS  PubMed  Google Scholar 

  43. van Besien K, Loberiza Jr FR, Bajorunaite R et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.

    CAS  PubMed  Google Scholar 

  44. Bierman PJ, Sweetenham JW, Loberiza Jr FR et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation – the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744–3753.

    PubMed  Google Scholar 

  45. Bishop MR . The graft-versus-lymphoma effect: fact, fiction, or opportunity? J Clin Oncol 2003; 21: 3713–3715.

    PubMed  Google Scholar 

  46. Grigg A, Ritchie D . Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004; 10: 579–590.

    CAS  PubMed  Google Scholar 

  47. Aoyama Y, Yamamura R, Shima E et al. Successful treatment with reduced-intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma. Ann Hematol 2003; 82: 371–373.

    CAS  PubMed  Google Scholar 

  48. Mandigers CMPW, Meijerink JPP, Raemaekers JMM et al. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet 1998; 352: 1522–1523.

    CAS  PubMed  Google Scholar 

  49. Nieto Y, Bearman SI, Shpall EJ et al. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. Bone Marrow Transplant 2001; 28: 1083–1086.

    CAS  PubMed  Google Scholar 

  50. Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028.

    CAS  PubMed  Google Scholar 

  51. Rodriguez R, Parker P, Nademanee A et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 2004; 33: 1123–1129.

    CAS  PubMed  Google Scholar 

  52. Carella A, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918–3924.

    CAS  PubMed  Google Scholar 

  53. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  54. Dreger P, Montserrat E . Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985–992.

    CAS  PubMed  Google Scholar 

  55. Jabbour E, Keating MJ, Champlin RE, Khouri IF . Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? Bone Marrow Transplant 2004; 34: 289–297.

    CAS  PubMed  Google Scholar 

  56. Khouri I, Keating MJ, Saliba R et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with allogeneic hematopoietic transplantation. Cytotherapy 2002; 4: 217–221.

    CAS  PubMed  Google Scholar 

  57. Doney KC, Chauncey T, Appelbaum FR et al. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 2002; 29: 817–823.

    CAS  PubMed  Google Scholar 

  58. Pavletic ZS, Arrowsmith ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717–722.

    CAS  PubMed  Google Scholar 

  59. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595–3599.

    CAS  PubMed  Google Scholar 

  60. Sohn SK, Bensinger W, Holmberg L et al. High-dose chemotherapy with allogeneic or autologous stem-cell transplantation for relapsed mantle cell lymphoma: the Seattle experience. Proc Am Soc Clin Oncol 1998; 17: 17a (abstract 64).

    Google Scholar 

  61. Corradini P, Ladetto M, Astolft M et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle cell lymphoma. Br J Haematol 1996; 94: 376–378.

    CAS  PubMed  Google Scholar 

  62. Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 97–99.

    CAS  PubMed  Google Scholar 

  63. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle cell lymphoma. J Clin Oncol 2003; 21: 4407–4412.

    CAS  PubMed  Google Scholar 

  64. Dasgupta RK, Morris E, Mackinnon S et al. Non-myeloablative stem cell transplantation (NST) for mantle cell lymphoma in the United Kingdom. A report of the clinical trials committee of the British Society for Blood and Bone Marrow Transplantation. Blood 2003; 102: 79a (abstract 265).

    Google Scholar 

  65. Escalon MP, Champlin RE, Saliba RM et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419–2423.

    PubMed  Google Scholar 

  66. Scalzulli PR, Corsetti MT, Baltrami G et al. Nonmyeloablative allografting for advanced lymphoma: a higher than expected remission rate and rate disease control. Blood 2003; 102: 467b (abstract 5596).

    Google Scholar 

  67. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

    CAS  PubMed  Google Scholar 

  68. Sureda A, Robinson S, Ruiz de Elvira C et al. Nonmyeloablative allogeneic stem cell transplantation significantly reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory Hodgkin's disease: results of the European Group for Blood and Bone Marrow Transplantation. Blood 2003; 102: 198a (abstr. 692).

    Google Scholar 

  69. Peggs KS, Thomson K, Chopra R et al. Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: evidence of a therapeutically relevant graft-versus-lymphoma effect. Blood 2003; 102: 198a (abstr. 694).

    Google Scholar 

  70. Porter DL, Stadtmauer EA, Lazarus HM . GVHD: graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning. Bone Marrow Transplant 2003; 31: 739–746.

    CAS  PubMed  Google Scholar 

  71. Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect is relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.

    PubMed  Google Scholar 

  72. Molina A, Zain J, Arber DA et al. Is allogeneic hematopoietic stem cell transplantation (AHSCT) potentially curative in a group of refractory cutaneous T-cell lymphomas (CTCLs)? Durable clinical, cytogenetic, and molecular remissions after AHSCT for refractory Sezary syndrome and mycosis fungoides. Blood 2003; 102: 476a (abstract 1737).

    Google Scholar 

  73. Buser AS, Heim D, Bucher C et al. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. Bone Marrow Transplant 2004; 33: 1011–1014.

    CAS  PubMed  Google Scholar 

  74. Tanimoto TE, Kusumi E, Hamaki T et al. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow Transplant 2003; 32: 131–137.

    CAS  PubMed  Google Scholar 

  75. Mitterbauer M, Kalhs P, Keil F et al. Continuous complete and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning. Br J Hematol 2002; 118: 132–135.

    Google Scholar 

  76. Bertz H, Illerhaus G, Veelken H, Finke J . Allogeneic hematopoietic stem cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning vs fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 12: 135–139.

    Google Scholar 

  77. Ballen KK, Becker PS, Emmons RVB et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancies. Blood 2002; 100: 442–450.

    CAS  PubMed  Google Scholar 

  78. Corradini P, Teralla C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produced clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75–82.

    CAS  PubMed  Google Scholar 

  79. Maloney DG . Graft-vs-lymphoma effect in various histologies of non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: S99–S105.

    PubMed  Google Scholar 

  80. Sohn SK, Baek JH, Kim DH et al. Successful allogeneic stem cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol 2000; 65: 75–80.

    CAS  PubMed  Google Scholar 

  81. Bethge WA, Hegenbart U, Stuart M et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103: 790–795.

    CAS  PubMed  Google Scholar 

  82. Peggs KS, Thomson K, Hart DP et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103: 1548–1556.

    CAS  PubMed  Google Scholar 

  83. Dey BR, McAfee S, Colby C et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320–329.

    PubMed  Google Scholar 

  84. Fung HC, Cohen S, Rodriguez R et al. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant 2003; 9: 649–656.

    CAS  PubMed  Google Scholar 

  85. Vose JM, Bierman PJ, Anderson JR et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142–2148.

    CAS  PubMed  Google Scholar 

  86. Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: 859–863.

    CAS  PubMed  Google Scholar 

  87. Radich J, Gooley T, Sanders JE et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272–279.

    CAS  PubMed  Google Scholar 

  88. Anderlini P, Giralt S, Andersson B et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615–620.

    CAS  PubMed  Google Scholar 

  89. Nagler A, Or P, Naparstek E et al. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000; 28: 1096–1104.

    CAS  PubMed  Google Scholar 

  90. Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022–4031.

    PubMed  Google Scholar 

  91. Mohty M, Bay J-O, Faucher C et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470–476.

    CAS  PubMed  Google Scholar 

  92. Izutsu K, Kanda Y, Ohno H et al. Development of grade II to IV acute GVHD is associated with lower incidence of disease progression after unrelated bone marrow transplantation for non-Hodgkin's lymphoma. A study from the Japan Marrow Donor Program. Blood 2003; 102: 490a (abstract 1783).

    Google Scholar 

  93. Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative vs conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    CAS  PubMed  Google Scholar 

  94. Johnson BD, Drobyski WR, Truitt RL . Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemic reaction without graft-versus-host disease. Bone Marrow Transplant 1993; 11: 329–336.

    CAS  PubMed  Google Scholar 

  95. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–1724.

    CAS  PubMed  Google Scholar 

  96. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bore marrow transplantation. A randomized control trial. Transplantation 1994; 57: 82–87.

    CAS  PubMed  Google Scholar 

  97. Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  98. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    CAS  PubMed  Google Scholar 

  99. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    CAS  PubMed  Google Scholar 

  100. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.

    CAS  PubMed  Google Scholar 

  101. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.

    CAS  PubMed  Google Scholar 

  102. Pelot MR, Pearson DA, Swenson K et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133–143.

    CAS  PubMed  Google Scholar 

  103. Sandmaier BM, Fukuda T, Gooley T et al. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. Exp Hematol 2003; 31: 168–175.

    CAS  PubMed  Google Scholar 

  104. Fukuda T, Storb R, Gooley T et al. DLA-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning: achievement of full donor chimerism by donor lymphocyte infusion. Blood 2003; 102: 458a (abstract 1670).

    Google Scholar 

  105. Taranova AG, Georges GE, Yunusov M et al. Breaking tolerance in stable mixed chimeric dogs with low-dose TBI and donor or recipient lymphocyte infusions. Blood 2003; 102: 76a (abstract 256).

    Google Scholar 

  106. Marijt WAE, Heemskerk MHM, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci 2003; 100: 2742–2747.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Takahashi Y, Mena O, Srinivasan R et al. Minor histocompatibility antigen (mHa) specific T-cells with cytotoxicity against autologous tumor cells can be isolated from patients with renal cell carcinoma having a GVT effect after nonmyeloablative hematopoietic cell transplantation (HCT). Blood 2003; 102: 701a (abstract 2594).

    Google Scholar 

  108. Bellucci R, Wu CJ, Chiaretti S et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656–663.

    CAS  PubMed  Google Scholar 

  109. Ganss R, Arnold B, Hammerling GJ . Mini review: overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 2004; 34: 22635–22641.

    Google Scholar 

  110. Mocellin S, Semenzato G, Mandruzzato S, Riccardo Rossi C . Part II: vaccines for haematological malignant disorders. Lancet Oncol 2004; 5: 727–737.

    CAS  PubMed  Google Scholar 

  111. Hope KJ, Jin L, Dick JE . Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738–743.

    CAS  PubMed  Google Scholar 

  112. Jordan CT . Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol 2004; 16: 708–712.

    CAS  PubMed  Google Scholar 

  113. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337–4343.

    CAS  PubMed  Google Scholar 

  114. Michalek J, Collins RH, Durrani HP et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci 2003; 100: 1180–1184.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–1724.

    CAS  PubMed  Google Scholar 

  116. Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201–1208.

    CAS  PubMed  Google Scholar 

  117. Kwak LW, Neelapu SS, Bishop MR . Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol 2004; 31: 37–46.

    PubMed  Google Scholar 

  118. Nachbaur D, Oberaigner W, Fritsch E et al. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience. Eur J Haematol 2001; 66: 43–49.

    CAS  PubMed  Google Scholar 

  119. Akpek G, Ambinder RF, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314–4321.

    CAS  PubMed  Google Scholar 

  120. Khouri IF, Lee M-S, Saliba RM et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia. Exp Hematol 2004; 32: 28–35.

    CAS  PubMed  Google Scholar 

  121. Casper J, Knauf W, Kiefer T et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725–731.

    CAS  PubMed  Google Scholar 

  122. Dreger P, Brand R, Hansz J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841–848.

    CAS  PubMed  Google Scholar 

  123. Rondon G, Giralt S, Huh Y et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669–672.

    CAS  PubMed  Google Scholar 

  124. Mandigers CMPW, Verdonck LF, Meijerink JPP et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32: 1159–1163.

    CAS  PubMed  Google Scholar 

  125. Ho AYL, Devereux S, Mufti GJ, Pagliuca A . Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. Bone Marrow Transplant 2003; 31: 551–557.

    CAS  PubMed  Google Scholar 

  126. Marks DI, Lush R, Cavenagh J et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108–3114.

    CAS  PubMed  Google Scholar 

  127. Mandigers CMPW, Raemaekers JMM, Schattenberg AVMB et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor risk relapsed low-grade non-Hodgkin's lymphoma. Br J Haematol 1998; 100: 198–206.

    CAS  PubMed  Google Scholar 

  128. van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of the graft-versus-lymphoma effect. Bone Marrow Transplant 1997; 19: 977–982.

    CAS  PubMed  Google Scholar 

  129. Grigg A, Bardy P, Byron K et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 1999; 23: 107–110.

    CAS  PubMed  Google Scholar 

  130. Anderlini P, Acholonu SA, Okoroji G-J et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD, and disease response. Bone Marrow Transplant 2004; 34: 511–514.

    CAS  PubMed  Google Scholar 

  131. Porter DL, Luger SM, Duffy KM et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 230–238.

    CAS  PubMed  Google Scholar 

  132. Grigg AP, Seymour JF . Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma 2002; 43: 889–892.

    CAS  PubMed  Google Scholar 

  133. Dreger P, van Biezen A, Brand R et al. Reduced-intensity conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL: a retrospective study on 448 patients. Blood 2003; 102: 197a (abstract 689).

    Google Scholar 

  134. Schetelig J, Thiede C, Bornhäuser M et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.

    CAS  PubMed  Google Scholar 

  135. Caballero MD, Martino R, León A et al. Nonmyeloablative transplant in patients with B-chronic lymphocytic leukemia (B-CLL): results of a prospective multicentre trial. Blood 2003; 102: 433b (abstract 5462).

    Google Scholar 

  136. Sorror ML, Maris M, Storer B et al. Nonmyeloablative (NM) conditioning and allogeneic hematopoietic cell transplantation (HCT) with HLA-matched unrelated donor (URD) for patients (pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL). Blood 2003; 102: 482a (abstr. 1757).

    Google Scholar 

  137. Khouri IF, Champlin RE . Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 2004; 31: 22–26.

    PubMed  Google Scholar 

  138. Dasgupta RK, Morris E, Mackinnon S et al. Non-myeloablative stem cell transplantation (NST) for mantle cell lymphoma in the United Kingdom. A report of the clinical trials committee of the British Society for Blood and Marrow Transplantation. Blood 2003; 102: 79a (abstract 265).

    Google Scholar 

  139. Sureda A, Robinson S, Ruiz de Elvira C et al. Nonmyeloablative allogeneic stem cell transplantation significantly reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory Hodgkin's disease: results of the European Group for Blood and Marrow Transplantation. Blood 2003; 102: 198a (abstract 692).

    Google Scholar 

  140. Peggs KS, Thomson K, Chopra R et al. Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: evidence of a therapeutically relevant graft-versus-lymphoma effect. Blood 2003; 102: 198a (abstract 694).

    Google Scholar 

  141. Cooney JP, Stiff PJ, Toor AA, Parthasarathy M . BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant 2003; 9: 177–182.

    PubMed  Google Scholar 

  142. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hematopoietic Cell Transplantation Program, University of Texas Southwestern Medical Center, Dallas, TX, USA

    B W Butcher & R H Collins Jr

Authors
  1. B W Butcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R H Collins Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R H Collins Jr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Butcher, B., Collins, R. The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant 36, 1–17 (2005). https://doi.org/10.1038/sj.bmt.1705008

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705008

Keywords

This article is cited by

Search

Advanced search

Quick links